Abstract
The 5-HT2C receptor is a highly complex, highly regulated receptor which is widely distributed throughout the brain. The 5-HT2C receptor couples to multiple signal transduction pathways leading to engagement of a number of intracellular signaling molecules. Moreover, there are multiple allelic variants of the 5-HT2C receptor and the receptor is subject to RNA editing in the coding regions. The complexity of this receptor is further emphasized by the studies suggesting the utility of either agonists or antagonists in the treatment of schizophrenia. While several 5-HT2C agonists have demonstrated clinical efficacy in obesity (lorcaserin, PRX-000933), the focus of this review is on the therapeutic potential of 5-HT2C agonists in schizophrenia. To this end, the preclinical profile of 5-HT2C agonists from a neurochemical, electrophysiological, and a behavioral perspective is indicative of antipsychotic-like efficacy without extrapyramidal symptoms or weight gain. Recently, the selective 5-HT2C agonist vabicaserin demonstrated clinical efficacy in a Phase II trial in schizophrenia patients without weight gain and with low EPS liability. These data are highly encouraging and suggest that 5-HT2C agonists are potential therapeutics for the treatment of psychiatric disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M (1995) Localization of the 5-hydroxytryptamine 2c receptor protein in human and rat brain using specific antisera. Neuropharmacology 24:1635–1645
Al-Janabi I, Arranz M, Blakemore A, Saiz P, Susce M, Glaser P, Clark D, de Leon J (2009) Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 19:305–311
Anderson I, Clark L, Elliott R, Kulkarni B, Williams S, Deakin J (2002) 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport 13:1547–1551
Bagdy G, Makara G (1995) Paraventricular nucleus controls 5-HT2C receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. Eur J Pharmacol 275:301–305
Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP (2008) A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharmacol Exp Ther 324:1084–1092
Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94–104
Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR Jr (2002) Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse 46:129–139
Blackburn TP, Suzuki K, Ashby CR Jr (2006) The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse 59:502–512
Chagnon YC (2006) Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 7:1681–1695
Clifton P, Lee M, Dourish C (2000) Similarities in the action of Ro 60-0175, a 5-HT2c receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology 152:256–267
Damjanoska K, Muma N, Zhang Y, D’Souza D, Garcia F, Carrasco G, Kindel G, Haskins K, Shankaran M, Petersen B, Van De Kar L (2003) Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist. J Pharmacol Exp Ther 304:1209–1216
Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587–597
Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53–61
Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002) Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71:727–734
Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1998) Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 37:265–272
Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999) SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195–1205
Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V (2003) RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem 87:1402–1412
Drago A, Serretti A (2009) Focus on HTR2C: a possible suggestion for genetic studies of complex disorders. Am J Med Genet 150B:601–637
Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson S (2005) WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 313:862–869
Egerton A, Ahmad R, Hirani E, Grasby P (2008) Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology (Berl) 200:487–496
Ellenbroek BA (2004) Pre-attentive processing and schizophrenia: animal studies. Psychopharmacology (Berl) 174:65–74
Ellingrod V, Perry P, Lund B, Bever-Stille K, Fleming F, Holman T, Miller D (2002) 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol 22:622–624
Ellingrod V, Perry P, Ringold J (2005) Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 134:76–78
Fletcher P, Tampakeras M, Sinyard J, Higgins G (2007) Opposing effects of 5-HT2A and 5-HT2C receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology 195:223–234
Frank M, Stryker M, Tecott L (2002) Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor. Neuropsychopharmacology 27:869–873
Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205–221
Gunes A, Dahl M-L, Spina E, Scordo MG (2008) Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 64:477–482
Gunes A, Scordo M, Jaanson P (2007) Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology 190:479–484
Heisler LK, Chu HM, Tecott LH (1998) Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann N Y Acad Sci 861:74–78
Herrick-Davis K, Grinde E, Niswender CM (1999) Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem 73:1711–1717
Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226–232
Hill MJ, Reynolds GP (2007) 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res 1149:14–17
Hoffman B, Mezey E (1989) Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett 247:453–462
Ikram H, Samad N, Haleem DJ (2007) Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. Pak J Pharm Sci 20:188–195
Kawahara Y, Grimberg A, Teegarden S, Mombereau C, Liu S, Bale T, Blendy J, Nishikura K (2008) Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci 28:12834–12844
Kenakin T (1995) Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232–238
Kostrzewa RM, Huang N-Y, Kostrzewa JP, Nowak P, Brus R (2007) Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox Res 11:41–50
Kozikowski AP, Cho SJ, Jensen NH, Allen JA, Svennebring AM, Roth BL (2010) HTS and rational drug design [RDD] to generate a class of 5-HT2C-selective ligands for possible use in schizophrenia. ChemMedChem 5:1221–1225
Kuzman M, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H (2008) The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 160:308–315
Lacivita E, Leopoldo M (2006) Selective agents for serotonin2C (5-HT2C) receptor. Curr Top Med Chem 6:1927–1970
Marazziti D, Rossi A, Giannaccini G, Zavaglia KM, Dell’Osso L, Lucacchini A, Cassano GB (1999) Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur Neuropsychopharmacol 10:21–26
Marquis KL, Dunlop J, Ramamoorthy S, Beyer CE, Lin Q, Brennan J, Piesla MJ, Ashby C, Harrison B, Magolda R, Pangalos MN, Stack G, Rosenzweig-Lipson S (2006) SCA-136: a novel 5-HT2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. Program No 934, Neuroscience Meeting Planner Atlanta, GA: Society for Neuroscience
Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486–496
Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Kohler C, Delft AM (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913–924
Masellis M, Basile V, Meltzer H, Lieberman J, Sevy S, Macciardi F, Cola P, Howard A, Badri F, Nothen M, Kalow W, Kennedy JL (1998) Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19:123–132
Mayers A, Baldwin D (2005) Antidepressants and their effect on sleep. Hum Psychopharmacol Clin Exp 20:533–559
Meltzer H, Maes M (1995) Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Biol Psychiatry 385:310–318
Miller KJ (2005) Serotonin 5-HT2C receptor agonists: potential for the treatment of obesity. Mol Interv 5:282–291
Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79–104
Mombereau C, Kawahara Y, Gundersen B, Nishikura K, Blendy J (2010) Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuropharmacology 59:468–473
Morris E, Normandin M, Schiffer W (2008) Initial comparison of ntPET with microdialysis measurements of methamphetamine-induced dopamine release in rats: support for estimation of dopamine curves from PET data. Mol Imaging Biol 10:67–73
Morris E, Yoder K, Wang C, Normandin M, Zheng Q, Mock B, Muzic RJ, Froehlich J (2005) ntPET: a new application of PET imaging for characterizing the kinetics of endogenous neurotransmitter release. Mol Imaging 4:473–489
Müller D, Kennedy JL (2006) Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7:863–887
Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M (2008) The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. Behav Brain Res 188:412–415
Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E (1999) RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 274:9472–9478
Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E (2001) RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 24:478–491
Niswender CM, Sanders-Bush E, Emeson RB (1998) Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci 861:38–48
Nonogaki K, Strack A, Dallman M, Tecott L (1998) Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 4:1152–1156
Park Y, Cho J, Kang S, Choi J, Lee S, Kim L, Lee H (2008) Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 33:55–60
Ramamoorthy P, Beyer C, Brennan J, Dunlop J, Gove S, Grauer S, Harrison BL, Lin Q, Malberg J, Marquis K, Mazandarani H, Piesla M, Pulicicchio C, Rosenzweig-Lipson S, Sabb A-M, Schechter L, Stack G, J Z (2006) Discovery of SCA-136, a novel 5-HT2C agonist, for the treatment of schizophrenia. 231st American Chemical Society National Meeting: MEDI-021
Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83–89
Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126:572–574
Reynolds G, Zhang Z, Zhang X (2002) Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086–2087
Reynolds GP, Templeman LA, Zhang ZJ (2005) The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 29:1021–1028
Rietschel M, Naber D, Finmmers R, Moller H, Propping P, Nothen M (1997) Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 8:1999–2003
Robinson ESJ, Dalley JW, Theobald DEH, Glennon JC, Pezze MA, Murphy ER, Robbins TW (2007) Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology 33:2398–2406
Rosenzweig-Lipson S, Beyer C, Hughes Z, Lin Q, Zhang M-Y, Grauer S, Comery T, Aschmies S, Stack G, Marquis K (2007a) Vabicaserin: Effects of a novel 5-HT2C agonist on prefrontal cortical neurotransmission, cognition and sensorimotor gating. European Neuropsychopharmacology The Journal of the European College of Neuropsychopharmacology 17(Supl.4):S484
Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL (2007b) Antidepressant-like effects of the novel, selective, 5-HT(2C) receptor agonist WAY-163909 in rodents. Psychopharmacology 192:159–170
Rosenzweig-Lipson S, Zhang J, Mazandarani H, Harrison BL, Sabb A, Sabalski J, Stack G, Welmaker G, Barrett JE, Dunlop J (2006) Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res 1073–1074:240–251
Sabb AL, Vogel RL, Welmaker GS, Sabalski JE, Coupet J, Dunlop J, Rosenzweig-Lipson S, Harrison B (2004) Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor. Bioorg Med Chem Lett 14:2603–2607
Sargent P, Sharpley A, Williams C, Goodall E, Cowen P (1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133:309–312
Segman R, Heresco-Levy U, Finkel B (2000) Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology 152:408–413
Sharpley A, Soloman R, Fernando A, da Roza DJ, Cowen P (1990) Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology (Berl) 101(4):568–569
Sharpley A, Vassaollo C, Cowen P (2000) Olanzapine increases slow-eave sleep; evidence for blockade of central 5-HT2c receptors in vivo. Biol Psychiatry 47:468–470
Shen et al. (2011) Neuropsychopharmacology 36:S75–S197. doi:10.1038/npp.2011.291
Shilliam CS, Dawson LA (2005) The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT2C receptor antagonist. Neuropsychopharmacology 30:372–380
Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (2007) CP-809,101, a selective 5-HT(2C) agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52:279–290
Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ (2001) RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 6:373–379
Stark J, McKie S, Davies K, Williams S, Luckman S (2008) 5-HT(2C) antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur J Neurosci 27:457–465
Tecott L, Sun L, Akana S, Strack A, Lowenstein D, Dallman M, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374:542–546
Templeman L, Reynolds G, Arranz B, San L (2005) Polymorphisms of the 5HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15:195–200
Tsuno N, Besset A, Ritchie K (2005) Sleep and depression. J Clin Psychiatry 66:1254–1269
Winstanley CA, Theobald DEH, Dalley JW, Glennon JC, Robbins TW (2004) 5-HT 2A and 5-HT 2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology 176:376–385
Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN (2006) Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets 5:445–452
Yevtushenko O, Cooper S, O’Neill R, Doherty J, Woodside J, Reynolds G (2008) Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 192:424–428
Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (2006) Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 71:521–529
Zhang Z, Zhang X, Sha W (2002) Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7:670–671
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Rosenzweig-Lipson, S., Comery, T.A., Marquis, K.L., Gross, J., Dunlop, J. (2012). 5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia. In: Geyer, M., Gross, G. (eds) Novel Antischizophrenia Treatments. Handbook of Experimental Pharmacology, vol 213. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25758-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-25758-2_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-25757-5
Online ISBN: 978-3-642-25758-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)